BUZZ-Dyax Corp: Set to open at 15-year highs after early-stage study success

** Drugmaker's shares jumps 47 pct to $24.72 premarket, levels not hit since the turn of the millennium

** Dyax (NasdaqGM: DYAX - news) 's lead experimental drug, DX-2930, was able to prevent nearly all hereditary angioedema (HAE) attacks, compared to a placebo, in an early stage study

** Strong data shows the drug could eclipse the current standard-of-care preventive treatment for HAE, analysts say

** All seven analysts covering the stock raise price targets; Wedbush nearly doubles PT to $35 from $18, both the biggest raise and now the highest target on Wall Street

** DX-2930 can reduce HAE attacks by 88-100 pct with only 2 injections/month vs. Shire Plc (Xetra: S7E.DE - news) 's Cinryze which reduces attacks by 50 pct with up to 12 injections, RBC (Other OTC: RBCI - news) 's Michael Yee says

** Cowen & Co says likely that DX-2930 will move straight to a key late-stage trial; expects market launch in 2018 and sales of $650 mln by 2021

** Stock had risen 19 pct this year through Tuesday, outperforming the 13 pct rise in the Nasdaq biotech index